Zevra Therapeutics Reveals Upcoming Q1 2025 Financial Results
Located in Celebration, Florida, Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) stands at the forefront of addressing the needs of individuals grappling with rare diseases. As a commercial-stage company devoted to creating innovative therapies, Zevra is well-prepared to present its financial and corporate results for the first quarter of 2025 on the upcoming Tuesday.
Details of the Financial Results Call
On the day of the call, Zevra will release key financial information and corporate updates following the market's close. Investors are encouraged to participate in the conference call at 4:30 p.m. ET. This will be a great opportunity for stakeholders to understand the company's performance, significant developments, and anticipated future projects.
How to Join the Conference Call
To join Zevra's financial results call, participants may dial:
- (800) 245-3047 for callers in the United States
- +1 (203) 518-9765 for international participants
- Conference ID: ZVRAQ125
This accessibility ensures a straightforward experience for all interested parties, allowing them to gather valuable insights directly from the company's executives.
Webcast Access and Replay
For those unable to join the live call, a replay will be made available for 90 days following the call at approximately 5:30 p.m. ET. Interested parties can access the replay through the “Events & Presentations” section of Zevra's Investor Relations webpage.
About Zevra Therapeutics, Inc.
Zevra Therapeutics is dedicated to transforming the landscape of rare disease treatment. The company combines rigorous scientific research with a strong commitment to addressing patient needs, resulting in the development of groundbreaking therapies. With a focus on rare diseases that often have insufficient treatment options, Zevra leverages data-driven methodologies to navigate the complexities inherent in drug development.
Commitment to Rare Diseases
By prioritizing the most pressing therapeutic needs, Zevra Therapeutics strives to enhance the quality of life for individuals living with rare diseases. The innovative approach taken by Zevra is designed not only to overcome existing development hurdles but also to streamline the process of bringing new therapies to those who need them the most.
Contact Information
For additional insights or queries, please reach out to:
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Frequently Asked Questions
What is the purpose of the Q1 2025 financial results call?
The call is designed to provide investors and stakeholders with updates on Zevra's corporate and financial performance for the first quarter of 2025.
When will the financial results be released?
Zevra plans to issue a news release detailing the financial results on the day of the call.
How can I participate in the conference call?
Participants can join the call by dialing the provided numbers for the United States or international callers, using the conference ID.
Is there a replay of the call available?
Yes, a replay of the conference call will be accessible for 90 days on Zevra's Investor Relations webpage.
What does Zevra Therapeutics focus on?
Zevra Therapeutics is committed to developing transformational therapies for patients with rare diseases that lack effective treatment options, utilizing innovative strategies to overcome challenges in drug development.
